AstraZeneca To Pay $4B For Cancer Treatment Developer
AstraZeneca will take a majority stake in Acerta Pharma for up to $4 billion, giving the U.K. pharmaceutical giant access to a blood cell cancer treatment as part of a greater push...To view the full article, register now.
Already a subscriber? Click here to view full article